BioNTech (BNTX) Competitors $99.26 +1.38 (+1.41%) Closing price 04:00 PM EasternExtended Trading$99.34 +0.07 (+0.08%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BNTX vs. GSK, TAK, ARGX, ONC, INSM, TEVA, GMAB, SMMT, ASND, and VTRSShould you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. BioNTech vs. Its Competitors GSK Takeda Pharmaceutical argenex BeOne Medicines Insmed Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Viatris BioNTech (NASDAQ:BNTX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends. Do analysts prefer BNTX or GSK? BioNTech currently has a consensus price target of $135.80, indicating a potential upside of 36.81%. GSK has a consensus price target of $37.38, indicating a potential downside of 6.66%. Given BioNTech's stronger consensus rating and higher probable upside, equities research analysts plainly believe BioNTech is more favorable than GSK.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.76GSK 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86 Does the media favor BNTX or GSK? In the previous week, GSK had 1 more articles in the media than BioNTech. MarketBeat recorded 17 mentions for GSK and 16 mentions for BioNTech. GSK's average media sentiment score of 1.26 beat BioNTech's score of 0.71 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 6 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GSK 13 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in BNTX or GSK? 15.5% of BioNTech shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, BNTX or GSK? BioNTech has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Which has stronger valuation and earnings, BNTX or GSK? GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNTech$2.98B8.01-$719.92M-$1.60-62.04GSK$40.10B2.03$3.29B$2.1618.54 Is BNTX or GSK more profitable? GSK has a net margin of 10.81% compared to BioNTech's net margin of -12.20%. GSK's return on equity of 49.22% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets BioNTech-12.20% -1.84% -1.59% GSK 10.81%49.22%11.31% SummaryGSK beats BioNTech on 10 of the 16 factors compared between the two stocks. Get BioNTech News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNTX vs. The Competition Export to ExcelMetricBioNTechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.53B$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-62.0421.1675.8626.51Price / Sales8.01446.35528.74123.58Price / CashN/A45.4037.1760.46Price / Book1.139.6212.796.29Net Income-$719.92M-$53.28M$3.28B$270.51M7 Day Performance-2.77%0.31%0.22%2.15%1 Month Performance-12.56%4.58%4.61%6.35%1 Year Performance-19.61%9.24%68.33%25.48% BioNTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNTXBioNTech2.5119 of 5 stars$99.26+1.4%$135.80+36.8%-20.7%$23.53B$2.98B-62.046,772GSKGSK1.9947 of 5 stars$40.06-1.1%$37.38-6.7%-6.3%$81.58B$40.10B18.5468,629Positive NewsDividend CutTAKTakeda Pharmaceutical2.4435 of 5 stars$15.27-0.9%N/A+2.6%$48.57B$30.09B50.8847,455High Trading VolumeARGXargenex3.9589 of 5 stars$768.00+2.3%$772.84+0.6%+40.7%$47.00B$2.25B39.381,599Positive NewsAnalyst DowngradeONCBeOne Medicines1.7507 of 5 stars$346.45+1.4%$330.89-4.5%N/A$37.97B$3.81B-200.2611,000INSMInsmed3.3097 of 5 stars$146.68+1.1%$139.86-4.7%+91.7%$30.67B$398.11M-25.691,271Positive NewsInsider TradeTEVATeva Pharmaceutical Industries2.7152 of 5 stars$19.30+1.8%$24.71+28.1%+2.7%$22.13B$16.54B-120.6136,830GMABGenmab A/S3.9323 of 5 stars$27.54flat$37.60+36.5%+4.1%$17.67B$3.12B13.842,682Positive NewsSMMTSummit Therapeutics3.3707 of 5 stars$19.44-25.2%$33.79+73.8%-40.7%$14.44B$700K-19.25110Positive NewsAnalyst ForecastHigh Trading VolumeASNDAscendis Pharma A/S2.9466 of 5 stars$205.22-0.3%$244.36+19.1%+63.2%$12.56B$393.54M-39.771,017Positive NewsVTRSViatris1.6033 of 5 stars$10.48-0.2%$10.40-0.8%-17.7%$12.22B$14.74B-3.6132,000 Related Companies and Tools Related Companies GSK Competitors Takeda Pharmaceutical Competitors argenex Competitors BeOne Medicines Competitors Insmed Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Summit Therapeutics Competitors Ascendis Pharma A/S Competitors Viatris Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BNTX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BNTX Stock Alerts